Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586206 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL912858 | 1.00 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL913345 | 0.90 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL913346 | 0.90 | LMNA (0.56) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL23253702 | 0.88 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15494655 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927890 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20516514 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL7147808 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL11223742 | 0.88 | LMNA (0.69) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2006-12-14 | — | — | US | claimed |
| US-7098195-B2 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | HEALTH RESEARCH, INC. (US) | 2006-08-29 | — | — | US | claimed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | claimed |
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | disclosed |
| WO-2019243672-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2019-12-26 | — | — | WO | disclosed |
| EP-2915539-B1 | Treatment of immunocompromised conditions with an E-Selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells | MATER MEDICAL RES INSTITUTE (AU) | 2018-09-19 | — | — | EP | disclosed |
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-9254322-B2 | Compositions comprising E-selectin antagonists and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-02-09 | — | — | US | disclosed |
| EP-2915539-A1 | Treatment of immunocompromised conditions with E-Selectin antagonist and G-CSF | Mater Medical Research Institute (AU) | 2015-09-09 | — | — | EP | disclosed |
| EP-2249854-B1 | TREATMENT OF IMMUNOCOMPROMISED CONDITIONS WITH E-SELECTIN ANTAGONIST AND G-CSF | MATER MEDICAL RES INST (AU) | 2015-01-21 | — | — | EP | disclosed |
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE | 2011-01-27 | — | — | US | disclosed |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | MATER MEDICAL RESEARCH INSTITUTE (AU) | 2011-01-06 | — | — | US | disclosed |
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7098195-B2 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | HEALTH RESEARCH, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1461046-A4 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | BRIGHAM & WOMENS HOSPITAL (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1461046-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003093410-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020270-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELL | LMNA 3138/4885KMT2A 2835/4885POLB 2739/4885 |
| US-20210402002-A1 | CONJUGATE | ST6GAL1, CSGALNACT1, FUT6 | LMNA 4446/4885KMT2A 2980/4885POLB 4520/4885 |
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | B3GAT3, UGGT1, FUT5 | LMNA 1769/4885KMT2A 3896/4885POLB 3985/4885 |
| US-20110002881-A1 | TREATMENT AND PROPHYLAXIS | SELP, SELE, SELPLG | LMNA 2539/4885KMT2A 2644/4885POLB 2177/4885 |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | FUT5, FUT6, OGT | LMNA 2371/4885KMT2A 3787/4885POLB 3533/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | LMNA 3637/4885KMT2A 3656/4885POLB 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.